|
시장보고서
상품코드
2050751
안지오텐신 전환효소(ACE) 억제제 시장 : 약제별, 적응증별, 투여 경로별, 유통 채널별 및 지역별Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, By Indication, By Route of Administration, By Distribution Channel, and By Region |
||||||
안지오텐신 전환효소(ACE) 억제제 시장은 2026년에 95억 2,230만 달러로 추정되고, 2033년에 141억 3,000만 달러에 이를 것으로 예상되고 있습니다. 또한, 2026-2033년 연평균 복합 성장률(CAGR)은 5.8%를 나타낼 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 95억 2,230만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 5.80% | 2033년 시장 규모 예측 : | 141억 3,000만 달러 |
안지오텐신 전환효소(ACE) 억제제는 주로 고혈압과 심부전 치료에 사용되는 약물의 일종입니다. 이들은 안지오텐신 II라는 호르몬의 작용을 억제함으로써 효과를 발휘합니다. 안지오텐신 II는 혈관을 수축시키고 알도스테론이라는 호르몬의 분비를 촉진하여 체내 수분과 염분 저류를 유발합니다. ACE 억제제는 안지오텐신 II의 생성을 억제하여 혈관을 이완, 확장시키고 체내 수분 저장량을 감소시켜 혈압을 낮추는데 도움을 줍니다. 일반적으로 배합되는 ACE 억제제에는 리시노프릴, 에날라프릴, 라미프릴 등이 있습니다. 부작용으로는 마른기침, 현기증, 신장 문제 등을 들 수 있습니다. ACE 억제제를 복용하는 사람은 신장 기능과 칼륨 수치를 모니터링하기 위해 정기적인 검진을 받는 것이 중요합니다. ACE 억제제는 안지오텐신 II의 작용을 완화하는 데 매우 중요한 역할을 하며, 혈관의 이완과 확장을 돕고 체액 저류를 조절하여 혈압을 낮추는 데 크게 기여합니다.
시장 역학
세계 안지오텐신 전환효소(ACE) 억제제 시장의 성장은 전 세계적으로 높은 고혈압 및 심장병 유병률에 기인합니다. 체내에서는 안지오텐신 호르몬인 안지오텐신(an-gee-o-ten-sin, 각 유형의 이름은 로마자로 표기)이 4가지 다른 형태로 생성됩니다. 안지오텐신 I은 ACE에 의해 안지오텐신 II로 전환되어 체내에 다양한 영향을 미칩니다. ACE 억제제는 특히 심혈관 질환과 고혈압에 자주 권장되는 약물입니다. 2019년에는 1,290만 명 이상의 메디케어 파트 D 가입자(전체 파트 D 수혜자의 약 27%)에게 ACE 억제제가 처방되었습니다. 물론 ACE 억제제는 부작용이 발생할 수 있습니다. 대부분은 경미하지만 일부는 위험하고 긴급한 의료 조치가 필요한 경우도 있습니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 수익 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다양한 매개 변수를 기반으로 세계 안지오텐신 전환효소(ACE) 억제제 시장의 주요 기업 프로파일을 작성했습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 세계 안지오텐신 전환효소(ACE) 억제제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 안지오텐신 전환효소(ACE) 억제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 안지오텐신 전환효소(ACE) 억제제 시장 : 약제별, 2021-2033년
제5장 세계의 안지오텐신 전환효소(ACE) 억제제 시장 : 적응증별, 2021-2033년
제6장 세계의 안지오텐신 전환효소(ACE) 억제제 시장 : 투여 경로별, 2021-2033년
제7장 세계의 안지오텐신 전환효소(ACE) 억제제 시장 : 유통 채널별, 2021-2033년
제8장 세계의 안지오텐신 전환효소(ACE) 억제제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
LSH 26.06.12Angiotensin Converting Enzymes (ACE) Inhibitors Market is estimated to be valued at USD 9,522.3 Mn in 2026 and is expected to reach USD 14,130.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9,522.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.80% | 2033 Value Projection: | USD 14,130 Mn |
Angiotensin converting enzymes (ACE) inhibitors are a type of medication used primarily in the treatment of high blood pressure and heart failure. They work by blocking the action of a hormone called angiotensin II. Angiotensin II causes blood vessels to constrict and promotes the release of another hormone called aldosterone, which leads to water and salt retention in the body. By inhibiting the production of angiotensin II, ACE inhibitors help to relax and widen the blood vessels, reduce the amount of water retained by the body, and therefore lower blood pressure. Commonly prescribed ACE inhibitors include lisinopril, enalapril, and ramipril. Side effects can include dry cough, dizziness, and kidney problems. It is important for individuals taking ACE inhibitors to have regular check-ups to monitor their kidney function and potassium levels. ACE inhibitors play a pivotal role in mitigating the effects of angiotensin II, aiding in the relaxation and widening of blood vessels while regulating fluid retention, thus contributing significantly to blood pressure reduction.
Market Dynamics
The global angiotensin converting enzymes (ACE) inhibitors market's growth is driven by the high prevalence of hypertension and heart disease globally. The body produces four distinct forms of the hormone angiotensin (an-gee-oh-ten-sin; the types' names are Roman numerals). Angiotensin I is converted to angiotensin II by ACE, which has a variety of bodily consequences. ACE inhibitors are often recommended, particularly for cardiovascular diseases and high blood pressure. An ACE inhibitor was given to over 12.9 million Medicare Part D participants in 2019 (or roughly 27% of all beneficiaries with Part D coverage). It is true that ACE inhibitors can cause negative effects. Most of them are mild, but a few are dangerous and require emergency medical attention.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global angiotensin converting enzymes (ACE) inhibitors market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novartis AG, Pfizer Inc., Merck & Co., AstraZeneca, Sanofi, Boehringer Ingelheim, GlaxoSmithKline, Lupin Limited, Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mylan and Other Prominent Players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global angiotensin converting enzymes (ACE) inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global angiotensin converting enzymes (ACE) inhibitors market.
Market Segmentation
- By Drugs (Revenue, USD Mn, 2021 - 2033)
- Benazepril
- Perindopril
- Trandfolapril
- Captopril
- Enalapril
- Lisinopril
- Others (Ramipril, etc.)
- By Indication (Revenue, USD Mn, 2021 - 2033)
- Hypertension
- Coronary Artery Disease
- Heart Failure
- Chronic Kidney Disease
- Scleroderma
- Others (Migraine, etc.)
- By Route of Administration (Revenue, USD Mn, 2021 - 2033)
- Oral
- Injectable
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top companies in Global Angiotensin Converting Enzymes (ACE) Inhibitors Market
- Novartis AG
- Pfizer Inc.
- Merck & Co.
- AstraZeneca
- Sanofi
- Boehringer Ingelheim
- GlaxoSmithKline
- Lupin Limited
- Torrent Pharmaceuticals Ltd.
- Reddy's Laboratories Ltd.
- Mylan
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Drugs
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Indication
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Route of Administration
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Distribution Channel
- Market Angiotensin Converting Enzymes (ACE) Inhibitors, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Rising prevalence of hypertension
- Growing Research and Development Activities
- Increasing Awareness of Cardiovascular Health
- Restraints
- Patent Expirations
- Side Effects and Safety Concerns
- Side Effects and Safety Concerns
- Opportunities
- Increasing Awareness of Cardiovascular Health
- Personalized medicine
- Combination therapies
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Drugs, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Benazepril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Perindopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Trandfolapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Captopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Enalapril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Lisinopril
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others (Ramipril, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Indication, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
- Coronary Artery Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
- Heart Failure
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
- Chronic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn )
- Scleroderma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Others (Migraine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
6. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Route of Administration, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
7. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
8. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drugs, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Mn)
- GCC
- Israel
- North Africa
- Central Africa
- Rest of Middle East & Africa
9. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
